Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation. We found that EZH2 protein expression is induced by interleukin 6 (IL-6) in growth factor-dependent cell lines and is constitutive in IL-6-independent cell lines. Furthermore, EZH2 expression correlates with proliferation and B-cell terminal differentiation. Significantly, EZH2 protein inhibition by short interference RNA treatment results in MM cell growth arrest. Conversely, EZH2 ectopic overexpression induces growth factor independence. We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N-or K-ras gene requires EZH2 activity. Finally, this is the first report to demonstrate that EZH2 has oncogenic activity in vivo, and that cell transformation and tumor formation require histone methyltransferase activity.
Introduction
Multiple myeloma (MM) is a plasma cell (PC) cancer characterized by the expansion of a malignant clone in the bone marrow. Several myeloma cell lines proliferate in response to interleukin 6 (IL-6), interaction with bone marrow stromal cells or expression of a constitutively active mutant ras gene (Jelinek et al., 1993; Billadeau et al., 1995; Cheung and Van Ness, 2001 ). We previously demonstrated that although these activating signals had a unique gene expression signature, they all induced expression of enhancer of zeste homolog 2 (ezh2) message when compared to nonproliferating controls (Croonquist et al., 2003) . EZH2 is a polycomb group (PcG) protein homolog to the Drosophila E(z) that mediates repression of gene activity at the chromatin level, likely through its methyltransferase activity (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002) . Besides its catalytic domain, EZH2 shares two highly conserved N-terminal domains with the fly E(z) called homology domain I and II (H-I and H-II) shown to mediate protein-protein interactions, a nuclear localization signal and a cystidine-rich domain or pre-SET domain. The pre-SET domain has been suggested to be required in binding of the PRC 2 complex to polycomb responsive elements (PREs) in Drosophila chromosomes (Carrington and Jones, 1996) . The best known, although not unique, targets of PcG complexes are the homeotic/hox genes. Two distinct PcG complexes have been shown to exist in Drosophila as well as mammals, PcGi or PRC 2 and PcGm or PRC 1. These complexes do not co-immunoprecipitate, suggesting no biochemical interaction exists between them. In mammals, the PcGi or PRC 2 complex is partially formed by EZH2/EED proteins; while the PcGm or PRC1 includes BMI-1 and MEL 18.
There is increasing evidence that different PcG proteins are deregulated during tumorigenesis. In particular, EZH2 is overexpressed in metastatic prostate cancer constituting an independent prognostic factor for this disease (Varambally et al., 2002) . There is additional evidence that this protein is a marker for aggressive breast cancer. In support for a role in oncogenesis, EZH2 overexpression in immortalized normal breast epithelial cells and mouse embryonic fibroblasts (MEFs) induced foci formation in soft agar assays (Bracken et al., 2003; Kleer et al., 2003) .
Interestingly, ezh2 was found to be one of the 30 genes that could distinguish between normal PC and MGUS (MM1) and aggressive myeloma (MM4) (Zhan et al., 2002) . In a subsequent study by the same group, ezh2 mRNA expression was studied in primary samples throughout B-cell development. Notably, ezh2 message expression was completely absent in normal bone marrow PC yet expressed in MM patient PC samples, correlating with tumor burden (highest in MM4 when compared to MM1-3) and recapitulating early B-cell developmental stages in which ezh2 is normally expressed (i.e. tonsillar B cells) (Zhan et al., 2003) . We therefore investigated how EZH2 expression was deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation.
Results

EZH2 protein expression is induced by IL-6 in growth factor-dependent MM cell lines and is constitutive in IL-6-independent MM cell lines
We previously demonstrated that ezh2 message expression is induced in growth factor-dependent ANBL-6.plxsn MM cells upon IL-6 stimulation and is constitutive in IL-6-independent ANBL-6.N-ras cells (Croonquist et al., 2003) . As EZH2 expression seems to correlate with proliferation in many different normal and malignant cell types, we investigated if EZH2 protein expression was also induced when cells received an activating signal (Varambally et al., 2002; Bracken et al., 2003) . IL-6-dependent MM cell lines ANBL-6.plxsn, Kas 6.1 and U266.p53 are cell cycle arrested upon IL-6 withdrawal and proliferate upon addition of growth factor (Jelinek et al., 1993; Westendorf et al., 1996; Rowley et al., 2000) . Figure 1a and b demonstrate that all IL-6-dependent MM cell lines tested express EZH2 protein when stimulated to proliferate by addition of 10 ng/ml of IL-6. However, EZH2 protein expression is virtually absent when these cell lines are cell cycle arrested by IL-6 starvation. ANBL-6 cells transfected with a mutant N-ras gene do not depend on Figure 1 EZH2 protein expression in MM cell lines correlates with cell proliferation. (a) Immunoblot demonstrating EZH2 protein expression induction upon stimulation with 10 ng/ml of recombinant IL-6 in ANBL-6.plxsn, Kas 6.1 and U266.p53 cell lines. Growth factor-independent MM cell lines, ANBL-6.N-ras, RPMI 8226 and U266.TAK express EZH2 protein constitutively. (b) Cells were treated with IL-6 and harvested for cell cycle analysis. Percentages of cells in each phase of the cell cycle were determined by flow cytometry. The number in the right corner represents the combined cell fraction in S and G2/M stages of the cell cycle IL-6 for growth (Billadeau et al., 1995 (Billadeau et al., , 1997 . IL-6-independent MM cell lines ANBL-6.N-ras, RPMI and U266.TAK express EZH2 protein constitutively, as seen in the immunoblot image in Figure 1a , and do not require IL-6 stimulation to proliferate (Figure 1b) . Other PcG protein members such as BMI-1 and EED are also expressed in these cell lines but their expression does not correlate with the proliferative state of the cells (data not shown).
EZH2 protein expression increases with proliferation and decreases during B-cell terminal differentiation
Our laboratory and others have previously demonstrated that the human B-lymphoblastoid CESS (IgGbearing) cell line terminally differentiates in the presence of IL-6 (Chen-Kiang, 1995; Cheung and Van Ness, 2002) . When IL-6 stimulated, these cells stop proliferating, they begin to secret IgG and after several days undergo apoptosis. This response is characteristic of normal mature B cells, but is opposite to the MM cell lines' phenotype that proliferate when IL-6 is added to the culture. In addition, there is evidence that primary bone marrow PCs isolated from normal donors do not express ezh2 in contrast to MM patient PC samples that do express this gene (Zhan et al., 2003) . Therefore, we examined the kinetics of EZH2 expression during B-cell terminal differentiation in contrast to MM cell proliferation. CESS cells terminally differentiate upon IL-6 stimulation for 6 days demonstrated by IgG secretion, cell cycle arrest, and increase the percentage of apoptotic cells; while the MM cell line proliferates in response to continuous growth factor stimulation (Figure 2a and b) . We found that while MM cell line ANBL-6.plxsn increased EZH2 protein expression over a period of 6 days upon continuous IL-6 stimulation, the B lymphoblastoid CESS cell line decreased EZH2 expression in the presence of IL-6 over the same period of time ( Figure 2c ).
Inhibition of EZH2 expression induces growth arrest in MM cell lines
We have demonstrated that EZH2 expression correlates with proliferation of MM cell lines (Figures 1 and 2 ). Previous evidence demonstrated that short interference RNA duplexes against the ezh2 message inhibited cell growth of the prostate cancer cell line PC3 (Varambally et al., 2002) . Therefore, we determined if EZH2 protein inhibition could trigger growth arrest of MM cell lines. We treated IL-6-dependent ANBL-6.plxsn and U266.p53, and IL-6-independent RPMI 8226 and U266.TAK cell lines with short interference RNA (siRNA) against EZH2 transcripts, GFP control siRNA or saline (mock). All cell lines were IL-6-starved for 3 days and transfected on day 4 by electroporation with siRNA. IL-6-dependent cell lines were treated with 0.5 ng/ml of IL-6 at the time of transfection to induce EZH2 expression. We stimulated the MM cell lines with 0.5 ng/ml of IL-6 in these experiments because it resembles more closely the physiological levels of IL-6 in the serum (0.8 ng/ml), and this is the minimum concentration of IL-6 at which cell lines divide in vitro and induce expression of EZH2. At 48 h post transfection, cells were labeled with [ 3 H]thymidine, harvested within 18 h and radio counted. Figure 3a demonstrates that both growth factor-dependent and -independent cell line growth was significantly inhibited after transfection with EZH2 siRNA when compared to GFP or mock controls, as shown by a 2-3-fold decrease in [ 3 H]thymidine incorporation. Furthermore, the growth inhibition correlated with a decrease in EZH2 protein expression as seen in the Western blot image in Figure 3b . Importantly, this phenotype was specific to EZH2 protein inhibition and not due to an interferon response after siRNA treatment in these cells, since the interferon-response protein PKR was phosphorylated at the same levels under EZH2, GFP siRNA or mock treatments in ANBL-6.plxsn cells, and not phosphorylated at all in any treated sample in RPMI 8226 cells (data not shown). Thus, we conclude, blocking EZH2 expression significantly inhibits MM cell growth.
EZH2 induces growth factor independence and enhances proliferation of MM cell lines
We next investigated if EZH2 ectopic overexpression in cell cycle-arrested (IL-6-dependent) cells lines would drive these cells into cycle and confer IL-6 independence. MM cell lines KAS 6.1, U266.p53 and ANBL-6.plxsn were IL-6 starved and transiently transfected by electroporation with expression plasmid DNA containing the EZH2 cDNA (myc-tagged) or empty vector. Cells were immediately plated after electroporation and treated with increasing concentrations of IL-6 or no interleukin treatment. After 48 h, lysates were prepared and cells were labeled with [ Figure 4a and data not shown). In the absence of IL-6, there was a significant proliferation induction in the EZH2 transfectants when compared to empty vector controls (threefold induction in ANBL-6.plxsn and Kas6.1 and twofold in U266.p53). Similarly, upon addition of increasing concentrations of IL-6, there was a significant enhancement of proliferation in the EZH2 transfectants when compared to empty vector control in all three cell lines. Figure 4b shows that myctag EZH2 protein was successfully transfected and expressed in these cells. In addition, we performed immunofluorescence in U266.p53 cells transiently transfected with the EZH2 containing expression plasmid (Figure 5a and b). We immunostained the cells with myc-tag antibody conjugated to alexa 546 fluorophore, Ki67 conjugated to FITC and DAPI for nucleic acids. EZH2 ectopic expression colocalized with the proliferative marker Ki67 in U266.p53 cells in the absence of IL-6 treatment, demonstrating that EZH2 protein was sufficient to drive these cells into cycle. Collectively, these data demonstrate that ectopic expression of EZH2 can confer proliferation enhancement and growth factor independence of MM cell lines.
Activated N-and K-ras proliferative phenotype in MM cell lines requires EZH2
The transcription factor E2F1 has been shown to bind the ezh2 promoter region and activate this gene during cell cycle progression (Bracken et al., 2003) . RAS controls at least three pathways that all converge in phosphorylation of RB and subsequent E2F1 activation of S phase genes, and activated N-and K-ras ANBL-6-transfected cells proliferate in the absence of IL-6. We investigated if this proliferative phenotype is EZH2 dependent (Billadeau et al., 1995 (Billadeau et al., , 1997 Sears and Nevins, 2002) . Mutant N-and K-ras ANBL-6 cells were electroporated with EZH2 or GFP siRNA duplexes and plated in the absence of IL-6. At 2 days post transfection, cells were radio labeled with [
3 H]thymidine, harvested within 18 h and counted. As shown in Figure 6a ANBL-6.N-ras and K-ras cell growth was significantly inhibited after treatment with EZH2 siRNA when compared to GFP siRNA controls (approximately 5-7-fold, respectively). Figure 6b shows that EZH2 protein expression was reduced after treatment with EZH2 siRNA compared to controls. Thus, we conclude that the activated RAS proliferative phenotype requires EZH2 expression.
EZH2 catalytic activity is required for cell transformation in vitro and tumor formation in vivo
Two groups have independently shown that EZH2 can transform either immortalized normal breast epithelial cells or mouse embryonic fibroblasts (Bracken et al., Kleer et al., 2003) . Thus, we next investigated which EZH2 domain was required for morphological transformation by creating mutations in different regions of the protein. We took advantage of reported mutations in mouse ezh2 and fly E(z) genes and mutated those same residues in the human ezh2 gene. The benefit of using the already reported mutations is that we could predict the molecular phenotype that resulted in each mutant. However, no functional phenotype has yet been reported at the cellular level.
As Figure 7a shows, we mutated a conserved histidine residue for alanine (H694A) in the asparagine, histidine and serine (NHS) consensus sequence shown to be required for histone methyltransferase (HMT) activity of several SET domain-containing proteins (Rea et al., 2000; Tachibana et al., 2001; Wang et al., 2001; Nishioka et al., 2002) . This mutation corresponds to histidine 689 in the mouse and Kuzmichev et al. (2002) showed that mutation H689A resulted in significantly reduced HMT activity in 293 cells. We created a mutation (C593Y) in the pre-SET or cystidine-rich domain. The mouse mutant C588Y, which corresponds to the fly mutation C545Y, has previously been shown to result in reduced HMT activity and a loss of PRC2 binding to chromosomes, respectively (Carrington and Jones, 1996; Kuzmichev et al., 2002) . We next created another mutation at the C-terminus end, R732K, that corresponds to the mouse mutant C727Y and fly mutant Immunoblots confirming knockdown of EZH2 protein expression upon transfection with EZH2 siRNA, GFP siRNA duplexes or mock. Relative expression levels, normalized to ACTIN, are given below the figure R741K shown to retain its ability to methylate histone 3 (Bajusz et al., 2001; Kuzmichev et al., 2002) . Finally, we created an N-terminus deletion mutant 130-138 del in homology domain box I. The H-1 domain is highly conserved with Drosophila E(z) and has been suggested to mediate protein-protein interactions of EZH2 to other PcG proteins such as EED (Denisenko et al., 1998) .
Transforming activity of the EZH2 mutations was assessed by the anchorage-independent growth of NIH3T3 cells in soft agar. All NIH3T3 EZH2 mutant stable transfectants express similar levels of protein (Figure 7b ). Figure 7c and Table 1 display the results of duplicate soft agar experiments where the wild-type EZH2 protein overexpression in NIH3T3 cells was able to induce morphological transformation of these cells resulting in a significant number of foci grown in soft agar. In contrast, EZH2 mutant H694A overexpression resulted in a fivefold reduction in foci formation similar to empty vector transfectants foci background levels. Surprisingly, mutant C593Y also showed significantly reduced foci numbers compared to wild-type transfectants; however, the number of foci formed was even lower than in controls suggesting the possibility of a dominant negative function. Both R732K and 130-138 deletion mutants showed a reduction in the number of foci formed when compared to wild type, but this decrease was not as significant as the one caused by either H694A or C593Y mutants.
As in vitro anchorage-independent growth does not always correlate with tumor formation in vivo, nude mice were inoculated by s.c. injection with NIH3T3 cells stably transfected with wild-type EZH2, H694 mutant cDNA containing plasmids, empty vector or parent cells. Mice were always injected in all four flanks. Tumors developed by week 3 postinjection and tumor volume was measured at this time and at 4 weeks. Wildtype EZH2 overexpressing tumors grew faster than H694 mutant-expressing tumors, while empty vector and parent cells did not develop any tumors by week 3 (0/8 empty vector tumors and 0/6 parent tumors) and only one very small tumor out of eight developed from the empty vector containing cells by week 4 (Figure 8a ). In addition, wild-type tumors were bigger and had a higher percentage of 5-bromo-2-deoxyuridine (Brdu)-positive cells than mutant tumors (Figure 8b and c) . This is the first report to demonstrate that EZH2 overexpression is sufficient to induce tumor formation in mice indicating that this protein is a true oncogene, and that its catalytic activity is required for oncogenic transformation both in vitro and in vivo.
Discussion
We have investigated the role of EZH2 deregulation in MM based upon the observation that this gene was induced under three different proliferative signals for the MM cell line ANBL6.plxsn (Croonquist et al., 2003) . Moreover, there is evidence that EZH2 correlates with proliferation in different cell types and tumor cell lines. Fukuyama et al. (2000) demonstrated that antisense ezh2 suppresses DNA synthesis in HL60 cells. In addition, overexpression of EZH2 in the Ramos B-cell line resulted in a twofold increase in proliferation rate (Visser et al., 2001 ). More recently, Varambally et al. (2002) demonstrated that siRNA duplexes targeting EZH2 in the prostate cell line PC3 induced significant growth inhibition. Therefore, we tested if our growth factor-dependent MM cell lines induced EZH2 protein when stimulated with IL-6 and conversely if our growth factor-independent cell lines constitutively expressed EZH2 protein. We found that in contrast to normal plasma cells that do not express ezh2, IL-6 stimulation induced EZH2 protein expression in growth factordependent cell lines while EZH2 was constitutively expressed in growth factor-independent cell lines.
There is also a body of evidence demonstrating that the distinct PcG complexes are expressed in a mutually exclusive manner throughout B-cell and peripheral Tcell development. Raaphorst et al. (2000) demonstrated that resting mantle B cells and follicular centrocytes mainly express BMI/RING or PRC 1 members, while actively dividing centroblasts are negative for these proteins and express EZH2/EED PRC 2 proteins. In another study, the same group showed that most mature peripheral T cells express BMI-1, whereas cycling T blasts express EZH2 instead ). In addition, EZH2 expression was downregulated upon in vitro differentiation of HL60 promyelocitic cells (Fukuyama et al., 2000) . Therefore, we investigated if EZH2 expression correlated with B-cell terminal differentiation. We and others have demonstrated that the Blymphoblastoid cell line CESS terminally differentiates upon continuous IL-6 stimulation (Chen-Kiang, 1995; Cheung and Van Ness, 2002) . In contrast, the MM cell line ANBL-6 proliferates in the presence of IL-6. We have demonstrated that EZH2 protein is induced and accumulates over time upon IL-6 stimulation in the MM cell line ANBL-6. In contrast, CESS cells, which constitutively express EZH2 in the absence of IL-6, lose EZH2 expression during terminal differentiation induced by IL-6. This study also suggests that EZH2 is required for MM cell growth since all MM cell lines Figure 5 Ectopic expression of EZH2 colocalizes with the Ki67 proliferative marker. (a) Immunostaining and immunofluorescence of U266.p53 cells transiently transfected with myc-tag EZH2. DAPI (blue) was used as a nuclear stain; anti-myc-tag primary antibody was probed with Alexa 546-conjugated secondary antibody (red) and anti-Ki67 with a FITC-conjugated secondry antibody (green). White arrow points at two nuclei (enlarged in b) where the colocalization of all three markers is significant. (b) Enlarge nuclei from (a) (white arrow) showing myc-tag EZH2 expression colocalized with the proliferative marker Ki67 studied were significantly growth inhibited upon EZH2 siRNA treatment. The reciprocal experiment showed this requirement as well, in which ectopic expression of EZH2 in nondividing IL-6-dependent cell lines induced proliferation and conferred growth factor independence. Although not all MM cell lines have been tested in this study, this is not the first SET domain containing protein that may be directly involved in MM. Another SET domain protein, the MMSET protein located on 4p16, is the target of a recurrent translocation in MM (Chesi et al., 1998) . However, this protein is not part of a PcG complex and the significance of this translocation is still under intense study.
We previously demonstrated growth factor independence in ANBL-6 cells stably transfected with a constitutively active mutant N-or K-ras transgene. While empty vector control cells require IL-6 for growth, the mutant N-or K-ras transfectants can grow in the absence of growth factor (Billadeau et al., 1995 (Billadeau et al., , 1997 . A recent report has linked cell cycle regulation to EZH2 expression. Specifically this group showed that under mitogenic conditions, the transcription factor E2F1 binds the ezh2 promoter and activates transcription during cell cycle progression (Bracken et al., 2003) . Since at least three RAS regulated pathways, MAPK/ MYC dependent, MAPK/MYC independent and RAF/ MAPK independent, converge in CYCLIN D/CDK4 activation, phosphorylation of pRB and release of E2F1 transcription factor to promote cell cycle progression (Sears and Nevins, 2002) , we asked if the proliferative phenotype of the mutant ras MM cells required EZH2 expression. Indeed, when we inhibited EZH2 protein in these cells, they were significantly growth arrested compared to siRNA control-treated cells. The data strongly suggest that in MM cells mutant RAS may be promoting growth by leading to the induction of EZH2.
Two recent reports have demonstrated that EZH2 can morphologically transform immortalized normal breast epithelial cells and mouse embryonic fibroblasts (Bracken et al., 2003; Kleer et al., 2003) . Furthermore, a mutant lacking the complete SET domain (which lacks HMT activity) was unable to transform these cells (Kleer et al., 2003) . However, one limitation of these studies is that the mutant used lacks a large portion of the C-terminus where the SET domain was deleted. It is possible that the phenotype observed in this mutant was not specific to the lack of catalytic activity but due to other structural changes in the protein when such a large portion was deleted. We decided to mutate a single amino acid in a consensus sequence (NHS) in the SET domain shared by many SET proteins such as Su(var)3-9, G9A, PR-Set7 and Set9 (Rea et al., 2000; Tachibana et al., 2001; Wang et al., 2001; Nishioka et al., 2002) . The conserved histidine residue in this consensus sequence has been shown to be critical for the methyltransferase activity of all these proteins (Rea et al., 2000; Tachibana et al., 2001; Wang et al., 2001; Nishioka et al., 2002) . In addition, a substitution of this histidine for alanine in the murine EZH2 has been shown to result in a significant reduction in HMT activity (Kuzmichev et al., 2002) .
We demonstrated that wild-type EZH2-expressing NIH3T3 cells are able to form foci in soft agar. In contrast, the H694A SET domain mutant did not transform these cells above background or control cells. Wild-type EZH2-expressing cells also developed sarcoma tumors faster and bigger than H694A mutant cells when inoculated into nude mice. NIH3T3 parent cells did form a few foci probably due to endogenous EZH2 activity but develop no tumors, as empty vector containing cells in vivo. Interestingly, the C593Y pre-SET domain mutant, which has been shown to be unable to bind chromatin in Drosophila and has reduced HMT activity in the mouse mutant, was virtually unable to form foci (number of foci below control background numbers). The fly allele C545Y is temperature-sensitive, and at the restrictive temperature, E(z) and other PcG proteins do not bind to PREs (Carrington and Jones, 1996) . However, the authors speculated that this phenotype is probably due to the loss of E(z) binding to other chromatin-binding partners in the complex since this domain does not bind DNA directly in vitro; therefore, it is presumably a protein-protein interaction domain that mediates binding of E(z) to chromosomes indirectly. Thus, we hypothesize that this mutant may be a dominant negative inhibiting the endogenous EZH2 protein by binding its complex partners that mediate chromosome binding. We expected the R732K protein to induce higher number of foci than wild type since the fly mutant is a gain of function (retains the ability of PcG proteins to bind PREs and can repress target gene expression better than wild-type EZH2) and the mouse mutant is not impaired in its methyltransferase activity (Bajusz et al., 2001; Kuzmichev et al., 2002) . However, this mutant showed fewer foci than wild type although this decrease was not as significant as the H694A mutant phenotype.
It has been shown that siRNA treatment against EED message could also inhibit cell growth (Bracken et al., 2003) . In addition, in vitro studies suggest that the Drosophila E(z) protein is over 1000-fold more active when complexed to its noncatalytic partners ESC (human EED), SU(Z)12 and NURF-55 than by itself (Cao et al., 2002; Muller et al., 2002) . It has been suggested that the H-1 domain is required for EZH2 binding to EED since the EZH2 39-159 aa fragment was the smallest clone found to interact with EED in an yeast two-hybrid screen (Denisenko et al., 1998) . Therefore, we deleted eight conserved residues at position 130-138 in H-1 domain. We observed a decrease in the number of foci formed by cells overexpressing this mutant but not as significant as the SET domain mutant H694A. Further mapping of the exact residues required for EZH2 binding to EED is needed to address whether EED activity is necessary for EZH2-induced transformation.
In summary, we have demonstrated that EZH2 is required for MM cell growth and the mutant ras phenotype. In addition, this is the first report to demonstrate that EZH2 acts as a true oncogene in vivo and that this activity requires an intact SET domain. Therefore, the catalytic domain of EZH2 could serve as a potential target for therapeutic design of methyltransferase inhibitors in the treatment of MM. The experiment was performed in duplicate
Material and methods
Cell culture
All cell lines were grown in RPMI, 10% fetal calf serum (FCS), 50 U/ml each penicillin and streptomycin, and 2 mM L-glutamine (Gibco BRL, Gaithersburg, MD, USA). Media were replaced every 4 days and supplemented with 0.5 ng/ml IL-6 (R&D Systems, Minneapolis, MN, USA). Human B-lymphoblastoid cell line CESS (IgG-bearing) was fed every 2 days in the absence of IL-6. Previous to the experiments, MM cell lines were incubated in the absence of IL-6 for 3 days to eliminate the IL-6 effect on the cells. On the third day, cells were centrifuged on Ficoll-Histopaque (Sigma Diagnostics, St Louis, MO, USA) to remove any dead cells and allowed to recover for 24 h. The cells were stimulated with 10 ng/ml of IL-6 when assaying for expression of PcG proteins or B-cell differentiation experiments for 48 h and 6 days, respectively; with 0.5 ng/ml for siRNA treatment experiments or no IL-6 treatment for EZH2 overexpression experiments. ANBL-6.plxsn, ANBL-6.N-ras 12 EE, ANBL-6.K-ras 12 EE, U266.TAK and U266.p53 transfected cells have been described previously (Billadeau et al., 1995 (Billadeau et al., , 1997 Rowley et al., 2000) . NIH3T3 cells were cultured in D-MEM, 10% FCS, 50 U/ml each penicillin and streptomycin and 2 mM L-glutamine (Gibco BRL, Gaithersburg, MD, USA) and fed every 2 days. Cells were trypsinized with Hanks solution supplemented with 2.5% trypsin (Gibco BRL, Gaithersburg, MD, USA) and 0.25 mM EDTA solution.
Analysis of cell cycle
In total, 2 Â 10 5 cells were collected and pelleted at the times indicated. They were then resuspended in 500 ml of hypotonic solution (50 mg/ml PI in 0.1% sodium citrate plus 0.1% Triton X-100) and incubated for at least 4 h at 41C in the dark. Analysis of the nuclei (both apoptotic and intact) was performed using FACSCalibur (Becton Dickinson, Mountain View, CA, USA). Apoptotic nuclei were detected as a heterogeneous subdiploid population to the left of intact nuclei in G 0 -G 1 in the histograms. Any changes in cell cycle distribution were also detected by the same method.
siRNA experiments EZH2 and GFP 21 bp duplexes were purchased from Dharmacon RNA technologies (Dharmacon, Inc., Lafayette, CO, USA) (Novina et al., 2002; Varambally et al., 2002) . MM cell lines were IL-6 starved for 3 days. On day 4, 10 Â 10 6 cells/200 ml/cuvette were transfected with 33 mg of EZH2, GFP siRNA duplexes or low serum medium (mock) by electroporation at 240 V/25 ms pulse length (square wave) and subsequently treated with 0.5 ng/ml of IL-6 to induce EZH2 expression in IL-6-dependent cell lines. At 48 h after transfection, cells were assayed for EZH2 protein expression by immunoblot or proliferation by [ 3 H]thymidine incorporation.
Transient transfections
IL-6-dependent MM cell lines were IL-6 starved as described and 10 Â 10 6 /200 ml/cuvette were transfected by electroporation at 240 V/25 ms pulse length (square wave) with 20 mg of either pMSCV empty vector or pMSCV.EZH2 cDNA (Clontech, Palo Alto, CA, USA). Cells were plated in the absence of IL-6 immediately after electroporation and at 48 h, assayed for EZH2 protein expression by immunoblot and proliferation by [ 3 H]thymidine incorporation.
Stable transfections
Human EZH2 cDNA cloned into the pcDNA3.1 plasmid (Invitrogen, Carlsbad, CA, USA) was a gift from Dr AP Otte, University of Amsterdam, The Netherlands. For some experiments, the human EZH2 cDNA was subcloned into the pMSCV puromycin-resistant vector (Clontech, Palo Alto, CA, USA). EZH2 mutant constructs were developed using the QuickChange Site directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's directions. The mutations were chosen based on published mouse EZH2 mutant data by Kuzmichev et al. (2002) , but using the human EZH2 cDNA sequence (accession # NM_004456). The 130-138 deletion mutant has not been previously reported. EZH2 mutant-, wild-type-and empty vector-containing plasmids were transfected into NIH3T3 cells using Lipofectamine 2000 (Gibco BRL, Gaithersburg, MD, USA) according to the manufacturer's instructions. At 48 h posttransfection, cells were selected with 400 mg/ml G-418 (Gibco BRL, Gaithers- 
Immunoblot and immunofluorescence
Briefly, 2-5 Â 10 6 cells were chilled on ice, harvested and lysed in ice-cold RIPA buffer (40 mM Tris-HCl pH 7.9, 0.1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA) supplemented with a protease inhibitor cocktail (Complete Mini, Roche, Basel Switzerland). Cells lysates were resolved on SDS-polyacrylamide gels and electrotransferred to a PVDF membrane. The membrane was blocked in 3% dry milk in PBS for 1 h and incubated with the primary antibodies at the appropriate dilution overnight at 41C, followed by incubation with secondary antibodies for 1 h at room temperature. The membranes were washed three times for 15 min each in PBS, developed using an enhanced chemiluminescence detection kit (Amersham, Arlington Heights, IL, USA) and exposed to X-ray films. Antibodies against EZH2 were kindly provided by Dr Otte. Anti-myc-tag was purchased from Cell Signaling Technologies (Beverly, MA, USA), anti-actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-human IgG and lambda light chain antibodies were purchased from Biosource International (Camarillo, CA, USA). For immunofluorescence, 1 Â 10 6 cells/well were plated in poly-I-lysine-coated coverslips on six-well plates. After incubation at 371C, cells were washed with PBS and fixed with prewarmed 1% paraformaldehyde followed by three washes in PBS. The samples were next permeabilized with 0.3% Triton X in PBS and washed three times in 0.3% Triton X and 0.2% Tween. Cells were incubated with primary antibodies, washed three times followed by secondary antibody incubation. Following three more washes, cells were stained with a 300 nM Dapi solution (Molecular Probes, Eugene, OR, USA) and washed three more times in PBS. Slides were allowed to dry overnight and analysed on Zeiss fluorescent microscope. Secondary antibodies conjugated to FITC and alexa 546 were purchased from Molecular Probes, Eugene, OR, USA.
Soft agar assays
Anchorage-independent growth assays were performed as described by Acs et al. (1997) with only minor modifications. Briefly, six-well plates were coated with 1.5 ml of 0.6% agarose-LE (USB, Cleveland, OH, USA) in D-MEM, 10% FCS, 50 U/ml each penicillin and streptomycin, and 2 mM L-glutamine (Gibco BRL, Gaithersburg, MD, USA). After solidification, 5000 cells/well were mixed with 1.5 ml of 0.3% agarose in the same medium as the bottom gel, and layered on top of the gel-coated wells. Once the top gel had solidified, 2 ml of media was added per well. Cells were fed every 2 days for 14 days and stained with 0.005% Crystal Violet for visualization and imaging of foci formation.
In vivo tumorigenicity experiments
Female BALB/c homozygous (nu/nu) mice, 6-8 weeks of age, were maintained in a pathogen-free environment throughout the experiments. Animals were inoculated by s.c. injection with NIH3T3 stable transfected cells (1 Â 10 6 cells/100 ml of media). Tumors developed were measured with a caliper at 3 and 4 weeks postinoculation. Animals were injected with Brdu (Sigma, St Louis, MO, USA) (100 mg/kg body weight) intraperitoneally at 4 weeks postinjection, killed an hour later and tumors were harvested, weighed and fixed with 10% formalin. Fixed tumor tissues were processed for Brdu staining by the Histopathology Core at the University of Minnesota.
